Extended Data Fig. 6: CRELD2 protein therapy after myocardial infarction (MI) in wild-type mice.
(a) Dosing regimen. CRELD2 (10 μg) was injected into the left ventricular (LV) cavity at the time of reperfusion and then subcutaneously infused for 7 days (10 μg/day). Control mice were treated with diluent (phosphate-buffered saline) only (bolus and infusion). (b) Scar size at 28 days. 6 mice per group. *P < 0.05 (two-sided independent samples t test). (c) Exemplary LV pressure-volume loops recorded at 28 days. (d) LV end-diastolic area (LVEDA) and LV end-systolic area (LVESA) as determined by echocardiography at 6 or 28 days. 7–10 mice per group. Data are presented as mean values ± SEM. (e) Fractional area change (FAC) as determined by echocardiography. Same mice as in (d). *P < 0.05, **P < 0.01 (two-sided independent samples t test). (f) TUNEL+ cardiomyocyte (CM) nuclei in the infarct border zone 24 hours after MI. 5 mice per group. *P < 0.05 (two-sided independent samples t test). (g) Isolectin B4 (IB4)+ endothelial cells in the infarct border zone 28 days after MI. 7–9 mice per group. *P < 0.05 (two-sided independent samples t test). Unless otherwise stated, individual data points, mean values, and SEMs are shown.
